AGIOS PHARMACEUTICALS INC

For the period ended Dec 31, 2023. Filed Feb 15, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 15, 2024

AGIO$31.76+1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(In thousands, except share and per share data) Years Ended December 31:	2023	2022	2021
Revenues:
Product revenue, net	$26,823	$11,740	$—
Milestone revenue	—	2,500	—
Total revenue	26,823	14,240	—
Operating expenses
Cost of sales	$2,881	$1,704	$—
Research and development	295,526	279,910	256,973
Selling, general and administrative	119,903	121,673	121,445
Total operating expenses	418,310	403,287	378,418
Loss from operations	(391,487)	(389,047)	(378,418)
Gain on sale of contingent payments	—	127,853	—
Royalty income from gain on sale of oncology business	—	9,851	6,639
Interest income, net	33,344	12,793	836
Other income, net	6,055	6,749	14,433
Net loss from continuing operations	(352,088)	(231,801)	(356,510)
Net income from discontinued operations, net of tax	—	—	1,961,225
Net (loss) income	$(352,088)	$(231,801)	$1,604,715
Net loss from continuing operations per share - basic and diluted	$(6.33)	$(4.23)	$(5.90)
Net income from discontinued operations per share - basic and diluted	$—	$—	$32.45
Net (loss) income per share - basic and diluted	$(6.33)	$(4.23)	$26.55
Weighted-average number of common shares used in computing net loss per share from continuing operations, net income per share from discontinued operations and net (loss) income per share – basic and diluted	55,651,487	54,789,435	60,447,346

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.